# High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

> **NCT04247633** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 578 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT04247633
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-11
- **Primary completion:** 2023-02
- **Final completion:** 2025-02
- **Target enrollment:** 578 (ESTIMATED)
- **Last updated:** 2020-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04247633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04247633, "High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04247633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*